Anti-CD22 immunotoxin CAT-8015
| Anti-CD22 immunotoxin CAT-8015 | |
|---|---|
| Term | Anti-CD22 immunotoxin CAT-8015 |
| Short definition | Anti-CD22 immunotoxin CAT-8015 (AN-tee. |
| Type | Cancer terms |
| Specialty | Oncology |
| Language | English |
| Source | NCI |
| Comments | |
Anti-CD22 immunotoxin CAT-8015 - (pronounced) (AN-tee. . . IH-myoo-noh-TOK-sin. . . ) drug used to treat adults with hairy cell leukemia who have come back or not improved with at least two other systemic therapies, including treatment with a purine nucleoside analogue (a type of cancer drug). The anti-CD22 immunotoxin CAT-8015 contains a monoclonal antibody that attaches to a protein called CD22, which is found on B cells (a type of white blood cell) and some types of leukemia cells. It also contains a bacterial toxin called PE38 that can help kill cancer cells. Anti-CD22 Immunotoxin CAT-8015 is a type of immunotoxin. Also called CAT-8015, Lumoxiti and Moxetumomab Pasudotox
External links
- Medical encyclopedia article on Anti-CD22 immunotoxin CAT-8015
- Wikipedia's article - Anti-CD22 immunotoxin CAT-8015
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski